Finally the degree in which the adverse effects of GLP-agonists on the neonate can be ascribed to maternal malnutrition could be assessed in multiple animal models where the female gets pregnant during either the catabolic stage of GLP-1 agonist exposure or after reaching a stable body weight. This evidence concerns the gene GCG and nutritional deficiency disease.